# US 6,727,346 B2 · Process for obtaining insulin precursors having correctly bonded cystine bridges

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,346 B2
- Document ID: US6727346B2
- Status: Granted
- Kind: B2
- Application number: 09/947,563
- Filed: 2001-09-07
- Published: 2002-10-24
- Granted: 2004-04-27
- Earliest claimed: 1997-08-18
- Assignees: Aventis Pharma Deutschland GmbH
- Inventors: Franz-Josef Rubröder; Reinhold Keller
- Web page: https://patentgrep.com/patent/US6727346B2

## CPC

- C07K 14/62: Insulins
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to an improved process for obtaining a precursor of an insulin or insulin derivative having correctly bonded cystine bridges in the presence of cysteine or cysteine hydrochloride and chaotropic auxiliary.

## Claims

### Claim 1

A process for obtaining an insulin or an insulin derivative thereof having correctly bonded cystine bridges in the presence of cysteine or cysteine hydrochloride and a chaotropic auxiliary, which comprises the following steps:
(a) mixing an aqueous suspension of a precursor of an insulin or an insulin derivative with an amount of cysteine or cysteine hydrochloride which results in approximately 1 to 15 SH residues of the cysteine or cysteine hydrochloride per cysteine residue of the precursor;
(b) adding the cysteine- or cysteine hydrochloride-containing suspension of the precursor into an approximately 4 to 9 molar solution of the chaotropic auxiliary at a pH of approximately 8 to 11.5 and a temperature of approximately 15° C. to 55° C., keeping the mixture obtained at this temperature for approximately 10 to 60 minutes;
(c) diluting the cysteine or the cysteine hydrochloride concentration to approximately 1 to 5 mM which results in a chaotropic auxiliary concentration of approximately 0.2 to 1.0 M in the mixture at a pH of approximately 8 to 11.5 and a temperature of approximately 5° C. to 30° C.;
(d) cleaving with trypsin or a trypsin-like enzyme the precursor of the insulin or the insulin derivative obtained by this process; and
(e) purifying the insulin or the insulin derivative having correctly bonded cystine bridges, wherein the precursor of the insulin or the insulin derivative of step (a) is obtained by expressing a fusion protein in a microorganism.

### Claim 2 (depends on 1)

The process according to claim 1, wherein the chaotropic auxiliary is guanidine or guanidine hydrochloride.

### Claim 3 (depends on 1)

The process according to claim 1, wherein the chaotropic auxiliary is urea.

### Claim 4 (depends on 1)

The process according to claim 1, wherein the concentration of the chaotropic auxiliary in step (b) is approximately 7.0 to 9 M.

### Claim 5 (depends on 1)

The process according to claim 1, wherein the temperature in step (b) is approximately 40° C.

### Claim 6 (depends on 1)

The process according to claim 1, wherein the pH in step (b) is approximately 10 to 11.

### Claim 7 (depends on 1)

The process according to claim 1, wherein the pH in step (c) is approximately 10 to 11.

### Claim 8 (depends on 1)

The process according to claim 1, wherein in step (c) the amount of water results in a dilution of the concentration of the cysteine or of the cysteine hydrochloride in the mixture to approximately 2.5 to 3 mM, and a concentration of the chaotropic auxiliary to approximately 0.5 M.

### Claim 9 (depends on 1)

The process according to claim 1, wherein
in step (a) the amount of cysteine or cysteine hydrochloride corresponds to an amount which results in 1 to 6 SH residues of the cysteine or cysteine hydrochloride per cysteine residue of the precursor,
in step (b) the cysteine- or cysteine hydrochloride-containing suspension of the precursor is added into an approximately 4 to 9 molar solution of the chaotropic auxiliary at a pH of approximately 8 to 11 and a temperature of approximately 30° C. to 45° C. and the mixture obtained is kept for approximately 20 to 40 minutes at this temperature; and
wherein the pH in step (c) is approximately 8 to 11 and the temperature is approximately 15° C. to 20° C.

### Claim 10 (depends on 9)

The process according to claim 9, wherein the concentration of the chaotropic auxiliary in step (b) is approximately 8 M, the temperature in step (b) is approximately 40° C., the pH in step (b) is approximately 10.6, the pH in step (c) is approximately 10.6 and in step (c) the amount of water results in a dilution of the concentration of the cysteine or of the cysteine hydrochloride in the mixture to approximately 2.5 to 3 mM and a concentration of the chaotropic auxiliary of approximately 0.5 M.

### Claim 11 (depends on 1)

The process according to claim 1, wherein
R2 is
a) a hydrogen atom, or
b) a peptide having 2 to 25 amino acid residues, comprising the amino acid residue arginine (Arg) at the carboxyl end of the peptide;
R1 is a phenylalanine residue (Phe);
(B2-B29) are the amino acid residues in the positions B2 to B29 of the B chain of human insulin;
Y is an amino acid residue from the group consisting of alanine (Ala), threonine (Thr) and serine (Ser);
X is the amino acid residue arginine (Arg) or a peptide having the amino acid sequence of the C chain of human insulin;
(A2-A20) are the amino acid residues in the positions A2 to A20 of the A chain of human insulin; and
R3 is an amino acid residue from the group consisting of asparagine (Asn), serine (Ser) and glycine (Gly).

### Claim 12 (depends on 1)

The process according to claim 1, further comprising cleavage of the precursor of the insulin or the insulin derivative obtained in step (d) with carboxypeptidase B or a carboxypeptidase-like enzyme.

### Claim 13 (depends on 1)

The process according to claim 1, wherein the insulin or the insulin derivative has a formula I of
in which
Y is a genetically encodable amino acid residue;
Z is
a) an amino acid residue from the group consisting of His, Arg and Lys,
b) a peptide having 2 or 3 amino acid residues, comprising the amino acid residue Arg or Lys at the carboxyl end of the peptide,
c) a peptide having 2 to 35 genetically encodable amino acids, comprising 1 to 5 histidine residues, or
d) OH;
R1 is a phenylalanine residue (Phe) or a covalent bond,
R3 is a genetically encodable amino acid residue, and wherein residues A2-A20 correspond to the amino acid sequence of
the A chain of an animal insulin, or an insulin derivative thereof; and wherein residues B2-B29 correspond to the amino acid sequence of the B
chain of an animal insulin or an insulin derivative thereof.

### Claim 14 (depends on 1)

The process according to claim 1, wherein
in step (a) the precursor of the insulin or the insulin derivative has the formula II
R2—R1—(B2-B29)—Y—X—Gly—(A2-A20)—R3 (II),
wherein
R2 is
a) a hydrogen atom,
b) an amino acid residue from the group consisting of lysine (Lys) and arginine (Arg), or
c) a peptide having 2 to 45 amino acid residues, comprising the amino acid residue lysine (Lys) or arginine (Arg) at the carboxyl end of the peptide;
R1 is a phenylalanine residue (Phe) or a covalent bond;
(B2-B29) are the amino acid residues in the positions B2 to B29 of the B chain of an animal insulin or an insulin derivative thereof;
Y is a genetically encodable amino acid residue;
X is
a) an amino acid residue from the group consisting of lysine (Lys) and arginine (Arg), or
b) a peptide having 2 to 35 amino acid residues, comprising the amino acid residue lysine (Lys) or arginine (Arg) at the N-terminal end and at the carboxyl end of the peptide, or
c) a peptide having 2 to 35 genetically encodable amino acids, comprising 1 to 5 histidine residues;
(A2-A20) are the amino acid residues in the positions A2 to A20 of the A chain of human insulin, animal insulin, or an insulin derivative thereof; and
R3 is a genetically encodable amino acid residue.

### Claim 15 (depends on 14)

The process according to claim 14, wherein
R2 is
a) a hydrogen atom, or
b) a peptide having 2 to 15 amino acid residues, at whose carboxyl end is found an arginine residue (Arg);
R1 is a phenylalanine residue (Phe);
(B2-B29) are the amino acid residues in the positions B2 to B29 of the B chain of human insulin;
Y is a threonine residue (Thr);
X is the amino acid residue arginine (Arg) or a peptide having 2 to 35 amino acid residues, where at the beginning and at the end of the peptide there are two basic amino acid residues, in particular arginine (Arg) and/or lysine (Lys);
(A2-A20) are the amino acid residues in the positions A2 to A20 of the A chain of human insulin; and
R3 is the amino acid residue asparagine (Asn) or glycine (Gly).

### Claim 16 (depends on 13)

The process of claim 13, wherein the insulin or the insulin derivative of formula I obtained corresponds to human insulin, wherein
Y is Thr (B30);
Z is OH;
R1 is Phe (B1);
R3 is Asn(A21);
A2-A20 is the amino acid sequence of the A chain of human insulin (amino acid residues 2 to 20) and B2-B29 is the amino acid sequence of the B chain of human insulin (amino acid residues 2 to 29).

### Claim 17 (depends on 13)

The process of claim 13, wherein the insulin or the insulin derivative of formula I obtained corresponds to human insulin, wherein
Y is Thr (B30);
Z is Arg—Arg;
R1 is Phe (B1);
R3 is Gly(A21); and
A2-A20 is the amino acid sequence of the A chain of human insulin (amino acid residues 2 to 20) and B2-B29 is the amino acid sequence of the B chain of human insulin (amino acid residues 2 to 29).

### Claim 18 (depends on 1)

The process according to claim 1, wherein the fusion protein is SEQ ID NO:4.

### Claim 19 (depends on 1)

The process according to claim 1, wherein the microorganism is Escherichia coil.

### Claim 20 (depends on 1)

The process according to claim 1, wherein the fusion protein is SEQ ID NO:5.
